Catalyst OrthoScience’s Catalyst CSR system for anatomic total shoulder replacement has faster improvements in function and pain reduction compared to stemmed and stemless systems, according to new data.
In the ninth peer-reviewed publication for the system researchers followed 179 patients who had surgery with Catalyst CSR, according to a June 4 news release. Patient-reported outcomes and functionality showed “clinically meaningful” improvements after six weeks from surgery, and 77% of patients had a Single Assessment Numeric Evaluation (SANE) score of at least 95 at their last follow-up.
Patients were followed five to eight years after surgery.
One implant-related revision happened after five years, and 1% of patients had low-grade medial calcar stress shielding.
“This real-world data further informs the orthopedic community of the effectiveness of a stemless, ellipsoid shaped humeral implant with a multiplanar osteotomy for a TSA,” Miguel Ramirez, MD, chief medical officer of Catalyst, said in the release. “It also underscores our focus on delivering a portfolio of clinically proven solutions that challenge the status quo to help improve the quality of life for the many people receiving a shoulder replacement today.”
The study was published in the Journal of Shoulder and Elbow Surgery.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.